Charles Schwab Investment Management Inc Xeris Biopharma Holdings, Inc. Transaction History
Charles Schwab Investment Management Inc
- $429 Billion
- Q1 2024
A detailed history of Charles Schwab Investment Management Inc transactions in Xeris Biopharma Holdings, Inc. stock. As of the latest transaction made, Charles Schwab Investment Management Inc holds 366,293 shares of XERS stock, worth $824,159. This represents 0.0% of its overall portfolio holdings.
Number of Shares
366,293
Previous 364,382
0.52%
Holding current value
$824,159
Previous $856,000
5.49%
% of portfolio
0.0%
Previous 0.0%
Shares
9 transactions
Others Institutions Holding XERS
# of Institutions
143Shares Held
57.3MCall Options Held
87.6KPut Options Held
80.4K-
Black Rock Inc. New York, NY9.96MShares$22.4 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA7.61MShares$17.1 Million0.0% of portfolio
-
Caxton Corp Princeton, NJ5.11MShares$11.5 Million69.8% of portfolio
-
Bio Impact Capital LLC Cambridge, MA4.17MShares$9.37 Million1.51% of portfolio
-
State Street Corp Boston, MA3.22MShares$7.23 Million0.0% of portfolio
About Xeris Biopharma Holdings, Inc.
- Ticker XERS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 135,956,992
- Market Cap $306M
- Description
- Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies for patient populations in endocrinology, neurology, and gastroenterology. The company markets Gvoke, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia; and Keveyis, a therapy for the treatment of hyperkalemic, h...